COVID‐19 vaccine in patients with dermal hyaluronic acid fillers in the tear trough: A retrospective study

Background Following authorization of two COVID-19 vaccinations in December 2020, media attention increased towards post-vaccine adverse events (AEs) in patients with facial dermal filler injections. Objectives The purpose was to characterize vaccine-related facial dermal filler AEs using the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database. Methods The MAUDE database was queried from January 1, 2011 to January 28, 2023 for facial dermal filler reports discussing vaccination-related AEs. A PubMed (National Institutes of Health, Bethesda, MD) literature review on dermal filler AEs was then conducted. Data were analyzed with descriptive statistics. Results Of 10,637 reports identified, 33 were included. There were 25 reports (75.8%) related to COVID-19 vaccination. Six reports (18.1%) were received before December 2020. There were 13 reports (39.4%) from February to June 2021 and 14 (42.4%) from September to December 2022. Hyaluronic acid-based fillers were described in 31 reports (93.9%). AEs were mostly reported within days post-injection (n=7, 21.2%), but ranged from immediately (n=2, 6.1%) to months (n=6, 18.2%) post-injection. Most AEs were reported post-vaccine (n=17, 51.5%) versus post-filler (n=14, 42.4%). In 26 reports (78.8%), AEs occurred at the site of filler injection. Most reports described inflammation/swelling (n=21, 28.0%). The literature review returned 302 articles, of which 14 were included. Only 1 article (7.1%) was published in a plastic surgery journal. Conclusions While the pandemic brought attention to COVID-19 vaccine-related facial dermal filler AEs, our study shows a low incidence compared to millions of vaccine and filler injections administered. The authors also document reactions with non-COVID-19 vaccines. Increased awareness may help providers counsel patients undergoing vaccination and dermal filler implantation.

show abstract

Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19

Yang

Tong

Chen

et al. 2022

Mol Biomed

View full text Add to dashboard Cite

COVID-19 caused by SARS-CoV-2 has created formidable damage to public health and market economy. Currently, SARS-CoV-2 variants has exacerbated the transmission from person-to-person. Even after a great deal of investigation on COVID-19, SARS-CoV-2 is still rampaging globally, emphasizing the urgent need to reformulate effective prevention and treatment strategies. Here, we review the latest research progress of COVID-19 and provide distinct perspectives on the mechanism and management of COVID-19. Specially, we highlight the significance of Human Identical Sequences (HIS), hyaluronan, and hymecromone (“Three-H”) for the understanding and intervention of COVID-19. Firstly, HIS activate inflammation-related genes to influence COVID-19 progress through NamiRNA-Enhancer network. Accumulation of hyaluronan induced by HIS-mediated HAS2 upregulation is a substantial basis for clinical manifestations of COVID-19, especially in lymphocytopenia and pulmonary ground-glass opacity. Secondly, detection of plasma hyaluronan can be effective for evaluating the progression and severity of COVID-19. Thirdly, spike glycoprotein of SARS-CoV-2 may bind to hyaluronan and further serve as an allergen to stimulate allergic reaction, causing sudden adverse effects after vaccination or the aggravation of COVID-19. Finally, antisense oligonucleotides of HIS or inhibitors of hyaluronan synthesis (hymecromone) or antiallergic agents could be promising therapeutic agents for COVID-19. Collectively, Three-H could hold the key to understand the pathogenic mechanism and create effective therapeutic strategies for COVID-19.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

COVID‐19 vaccine in patients with dermal hyaluronic acid fillers in the tear trough: A retrospective study

Cited by 3 publications

References 7 publications

Hyaluronic-acid/tozinameran

Hyaluronic-acid/tozinameran

Facial Dermal Filler Injection and Vaccination: A 12-Year Review of Adverse Event Reporting and Literature Review

Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19

Contact Info

Product

Resources

About